Although the incidence of ICI-induced BP significantly differed on the basis of cancer type, <i>COL17A1</i> mutations or dysregulation do not appear to drive this phenomenon, suggesting alternative immune mechanisms. This evidence concerns the gene COL17A1 and cancer.